Cryopreservation Of Gametes And Embryos — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cryopreservation of gametes (eggs and sperm) and embryos is a fundamental component of modern reproductive medicine — the process of preserving biological material for potential future use by cooling to ultra-low temperatures where biological activity is indefinitely suspended. The primary technique used in contemporary embryology is vitrification (from Latin 'vitreum' — glass) — an ultra-rapid freezing protocol using high concentrations of cryoprotectant agents that transitions the biological material into a glass-like amorphous solid state (rather than forming ice crystals, which cause lethal cellular damage) in milliseconds by plunging the specimen directly into liquid nitrogen at -196°C. Vitrification has revolutionised gamete and embryo cryopreservation since its widespread adoption in the 2000s-2010s, achieving oocyte survival rates of 90-95%, embryo survival rates of 95-98%, and pregnancy rates from frozen-thawed embryo transfer (FET) cycles that are now equivalent to or exceeding fresh embryo transfer cycles in many programmes.

The process of cryopreservation involves: (1) controlled ovarian stimulation (COS) to produce multiple mature oocytes (for egg freezing), or the natural IVF stimulation cycle (for embryo freezing after fertilisation); (2) oocyte retrieval under ultrasound guidance under sedation/anaesthesia; (3) fertilisation (for embryo cryopreservation); (4) embryo culture to blastocyst stage (day 5-6) for optimal selection; (5) vitrification using cryoprotectants (DMSO, ethylene glycol, propylene glycol) at precisely controlled concentrations and exposure times; (6) sealed storage in liquid nitrogen cryotanks at -196°C; and (7) when needed in the future, thawing (warming) using the reverse protocol with gradual cryoprotectant dilution and rehydration, followed by either intrauterine transfer (embryos) or fertilisation with sperm (eggs).

Sperm cryopreservation is the most established gamete preservation modality, used since the 1950s. Fresh ejaculate, surgically retrieved sperm (TESE, PESA, TESA), or donor sperm is extended in cryoprotective medium and slowly cooled (slow-rate freezing is standard for sperm, unlike the vitrification required for oocytes and embryos). Post-thaw sperm motility is typically 30-50% of pre-freeze levels, which is sufficient for intrauterine insemination or ICSI (intracytoplasmic sperm injection).

Oncofertility — fertility preservation for cancer patients before gonadotoxic treatments — is the most medically urgent indication for cryopreservation. Chemotherapy (particularly alkylating agents — cyclophosphamide, procarbazine) and pelvic/gonadal radiation cause premature ovarian insufficiency in females (irreversible loss of ovarian function) and azoospermia (permanent absence of sperm) in males. Sperm banking before cancer treatment initiation is recommended for all males of reproductive age; oocyte or embryo vitrification is recommended for females who can safely delay cancer treatment for 2-4 weeks for ovarian stimulation. Testicular tissue cryopreservation (for prepubertal boys) and ovarian tissue cryopreservation (for girls and women unable to delay treatment) are developing techniques.

Surplus IVF embryos are stored after fresh embryo transfer — allowing additional frozen embryo transfer (FET) cycles from the same stimulation without repeat COS. Elective oocyte cryopreservation (social egg freezing) for women wishing to preserve fertility while pursuing education, career, or relationship goals is now widespread — offering women the possibility of using their younger, higher-quality eggs for future pregnancy. Cryopreservation of donor gametes (sperm and oocytes) is the foundation of donor egg and donor sperm IVF programmes, enabling cross-programme coordination, quarantine testing of donations, and flexible use. Preimplantation genetic testing for aneuploidies (PGT-A) or monogenic disorders (PGT-M) requires embryo biopsy and cryopreservation while awaiting genetic results.

Any male with testes producing sperm is a candidate for sperm cryopreservation — the process is simple (masturbation-produced sample or surgical extraction), non-invasive, and appropriate before any treatment that may compromise future fertility (chemotherapy, radiation, gender-affirming hormone therapy, orchiectomy). Female patients eligible for oocyte or embryo cryopreservation include: any woman with a cancer diagnosis that requires gonadotoxic treatment, with 2-4 weeks available for stimulation; premenopausal women with premature ovarian insufficiency-causing conditions requiring treatment; women undergoing prophylactic bilateral oophorectomy (e.g., BRCA mutation carriers); and women electively wishing to preserve fertility, ideally under age 38 (egg quality declines significantly after 38, and under 35 is optimal).

Contraindications to ovarian stimulation for oocyte cryopreservation include oestrogen-receptor-positive breast cancer (stimulation increases oestrogen levels — modified tamoxifen or letrozole protocols are used instead to avoid high oestrogen exposure), known poor ovarian reserve (antral follicle count <3, AMH <0.4 ng/mL — minimal yield expected from stimulation, though not an absolute contraindication), and significant medical conditions precluding oocyte retrieval under sedation or anaesthesia. Embryo cryopreservation requires a sperm source (partner's sperm or donor sperm) — for single women without a partner, oocyte cryopreservation is the appropriate route.

Oocyte vitrification (egg freezing) is performed following controlled ovarian stimulation (7-14 days of daily gonadotropin injections to recruit multiple follicles), egg retrieval under ultrasound guidance under sedation, and immediate vitrification of mature metaphase II oocytes using closed or open carrier systems. Blastocyst-stage embryo vitrification (day 5-6) is preferred over cleavage-stage (day 2-3) embryo cryopreservation for the superior implantation rates of blastocysts and the ability to select the highest-quality embryos from the cohort. Ovarian cortex cryopreservation — surgically harvesting ovarian tissue strips, vitrifying them, and later reimplanting them to restore ovarian function — is performed for girls and women unable to delay cancer treatment for stimulation, though the technique remains experimental for malignancies with risk of ovarian involvement.

Frozen embryo transfer (FET) protocols include natural-cycle FET (monitoring for spontaneous ovulation and transferring the embryo synchronised with the natural luteinising hormone surge — suitable for women with regular cycles) and hormone replacement therapy (HRT) FET (administering oestrogen and progesterone to build the endometrium without ovulation — provides scheduling flexibility and consistent endometrial preparation). Endometrial receptivity testing (ERA — Endometrial Receptivity Analysis, a genomic test of the endometrial biopsy to identify the personalised implantation window) is an emerging tool used before FET to optimise transfer timing in repeat implantation failure cases.

Vitrification has dramatically improved cryopreservation outcomes compared to the older slow-freezing techniques. Post-warm oocyte survival rates with vitrification are 90-95% in experienced embryology laboratories, compared to 50-70% with slow-rate freezing. Fertilisation rates of surviving vitrified oocytes are equivalent to fresh oocytes at 70-80% (with ICSI). Live birth rates per thawed embryo transfer cycle at experienced IVF centres are 40-65% for patients under 38 using their own vitrified embryos, and comparable to fresh embryo transfer in many programmes.

For cancer patients preserving fertility before gonadotoxic treatment, cryopreservation provides the only realistic opportunity for future genetic parenthood. Studies document live birth rates of 30-50% per FET cycle in cancer survivors using embryos or oocytes preserved before cancer treatment, depending on age at preservation and cancer treatment received. For elective egg freezing, a 2016 study in Fertility and Sterility found a 12-year cumulative live birth rate of 85% for women who froze eggs under age 35 and used them before age 43. Social egg freezing provides significant psychological benefit — reduced reproductive anxiety and improved sense of control over fertility choices — though the majority of women who freeze eggs for social reasons do not ultimately use them if they achieve natural pregnancy.

Ovarian stimulation for oocyte retrieval carries the risk of ovarian hyperstimulation syndrome (OHSS) — potentially life-threatening ovarian enlargement, fluid accumulation, electrolyte disturbance, and thrombosis from excessive follicular response to gonadotropins. Modern protocols using GnRH antagonists with GnRH agonist trigger (instead of hCG trigger) have dramatically reduced severe OHSS rates to below 1%. Oocyte retrieval (transvaginal, ultrasound-guided needle aspiration) carries risks of bleeding (clinically significant in <1% requiring intervention), infection (pelvic infection in 0.3-0.5%), and rare injury to adjacent structures (bowel, bladder, blood vessels).

Cryopreservation itself has not been demonstrated to increase the rate of congenital abnormalities or long-term health effects in children born from frozen gametes and embryos — extensive follow-up data from thousands of FET children confirm reassuring safety data. However, there is emerging evidence that HRT-prepared FET cycles (as opposed to natural-cycle FET) may be associated with a modest increase in hypertensive disorders of pregnancy, warranting continued monitoring. Long-term storage in liquid nitrogen at -196°C does not cause progressive DNA damage if storage conditions are maintained. Unexpected storage tank failure or natural disaster — though rare — could result in loss of stored material; established IVF centres have redundant storage protocols and emergency backup systems.

After oocyte retrieval, patients experience mild to moderate pelvic discomfort, bloating, and light vaginal spotting for 1-5 days — managed with paracetamol and rest. Instructions to report severe pain, significant abdominal distension, marked urinary changes, or fever are given for early identification of OHSS or infection. Follow-up with the reproductive medicine team at 1 week for OHSS monitoring in high-risk patients. Storage contracts require annual administrative review and payment of storage fees (typically GBP/USD 200-400 per year for sperm; USD 500-1,000 for eggs or embryos depending on facility).

Patients with stored gametes or embryos should be clearly informed about the legal storage duration permitted in their country (10 years extendable under certain circumstances in the UK under the HFEA; varies internationally), consent for use by a surviving partner, and disposal options (discarding, donation to another patient, or donation to research) when storage is discontinued. Regular communication with the IVF centre maintaining storage ensures that consent remains current and contact details are maintained. Patients should review their storage status before major life events (marriage, divorce, partner's death) given the legal complexities that can arise.

Oocyte cryopreservation in the USA costs USD 10,000-15,000 for the stimulation cycle and retrieval, plus USD 500-1,000 per year for storage. A subsequent FET cycle adds USD 4,000-6,000. In the UK, NHS funding is available for egg freezing before cancer treatment in most Clinical Commissioning Groups; social egg freezing is self-funded at GBP 3,000-5,000 per cycle plus storage. Sperm banking is very affordable (USD 100-300 for collection and initial freeze; USD 200-400 per year storage).

Medical tourism for fertility preservation and IVF is a large and well-established sector. India, Spain, Czech Republic, and Cyprus offer egg freezing and embryo cryopreservation at 40-60% of UK/USA prices with equally modern vitrification techniques and well-qualified embryologists. Egg freezing in India at accredited IVF clinics costs USD 2,000-4,000 per cycle; Spain and Czech Republic offer comprehensive IVF/egg freezing packages at EUR 2,500-4,500. For cancer patients requiring urgent fertility preservation before chemotherapy, accredited oncofertility centres in India and Thailand provide prompt access to stimulation protocols on timelines comparable to Western oncofertility programmes, at substantially lower cost.

For women, alternatives to cryopreservation for fertility preservation include: ovarian transposition (oophoropexy — surgically moving the ovaries out of the pelvic radiation field before radiotherapy) to protect ovarian function from localised pelvic irradiation; GnRH agonist co-treatment during chemotherapy (suppresses the ovaries temporarily to reduce gonadotoxic exposure — evidence remains inconclusive but widely used); and adoption or surrogacy using donor eggs as alternatives to genetic parenthood if cryopreservation was not performed or was unsuccessful.

For elective fertility preservation, natural conception remains possible for women who do not freeze eggs and are under 40 — egg freezing is a risk management strategy for uncertain future circumstances, not a necessary intervention for every woman. Embryo adoption (using donated embryos from other couples) is an alternative to cryopreserving one's own gametes for women who wish to experience pregnancy but do not prioritise genetic parenthood. For males, options if sperm banking was not performed include hormonal stimulation (FSH, LH, clomiphene) to restore spermatogenesis after chemotherapy, and microsurgical sperm extraction (micro-TESE) to find rare residual spermatozoa in the testes of men with post-treatment azoospermia.